Mirati Therapeutics (MRTX) Tops Q4 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Mirati Therapeutics (MRTX) Tops Q4 EPS by 6c

Mirati Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update

March 11, 2015 8:00 AM EDT

SAN DIEGO, March 11, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the fourth quarter and twelve months ended December 31, 2014 and provided an update on its drug development programs.

"Mirati was built on the premise that the best way to improve outcomes for patients with cancer is to treat the specific genetic and epigenetic drivers of their cancer," said Charles M. Baum, M.D., Ph.D., president and CEO, Mirati. "In 2014, we made significant progress across our clinical programs in non-small cell lung cancer,... More